Jaya Sivaswami Tyagi

Prof. Jaya Sivaswami Tyagi


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2018 in ACS Infectious Diseases
Verified
Journal Article
Closed access
SLSurabhi Lavania
Surabhi Lavania
RDRitu Das
Ritu Das
ADAbhijeet Dhiman
Abhijeet Dhiman
VMVithal Prasad Myneedu
Vithal Prasad Myneedu
AVAjoy Verma
Ajoy Verma
JTJaya Sivaswami Tyagi
Jaya Sivaswami Tyagi

1 May 2018 in Redox Biology
Verified
Journal Article
Open access
KSKriti Sikri
Kriti Sikri
PDPriyanka Duggal
Priyanka Duggal
CKChanchal Kumar
Chanchal Kumar
SBSakshi Dhingra Batra
Sakshi Dhingra Batra
AVAtul Vashist
Atul Vashist
JTJaya Sivaswami Tyagi
Jaya Sivaswami Tyagi
Bacterial dormancy is a major impediment to the eradication of tuberculosis (TB), because currently used drugs primarily target actively replicating bacteria. Therefore, decoding of the critical survival pathways in dormant tubercle bacilli is a research priority to formulate new approaches for killing these bacteria. Employing a network-based gene expression analysis approach, we demonstrate that redox active vitamin C (vit C) triggers a multifaceted and robust adaptation response in Mycobacterium tuberculosis (Mtb) involving ~ 67% of the genome. Vit C-adapted bacteria display well-described features of dormancy, including growth stasis and progression to a viable but non-culturable (VBNC) state, loss of acid-fastness and reduction in length, dissipation of reductive stress through triglyceride (TAG) accumulation, protective response to oxidative stress, and tolerance to first line TB drugs. VBNC bacteria are reactivatable upon removal of vit C and they recover drug susceptibility properties. Vit C synergizes with pyrazinamide, a unique TB drug with sterilizing activity, to kill dormant and replicating bacteria, negating any tolerance to rifampicin and isoniazid in combination treatment in both in-vitro and intracellular infection models. Finally, the vit C multi-stress redox models described here also offer a unique opportunity for concurrent screening of compounds/combinations active against heterogeneous subpopulations of Mtb. These findings suggest a novel strategy of vit C adjunctive therapy by modulating bacterial physiology for enhanced efficacy of combination chemotherapy with existing drugs, and also possible synergies to guide new therapeutic combinations towards accelerating TB treatment.

1 September 2018 in Tuberculosis
Verified
Journal Article
Closed access
ADAbhijeet Dhiman
Abhijeet Dhiman
SHSagarika Haldar
Sagarika Haldar
SMSubodh Kumar Mishra
Subodh Kumar Mishra
NSNeera Sharma
Neera Sharma
ABAnjali Bansal
Anjali Bansal
JTJaya Sivaswami Tyagi
Jaya Sivaswami Tyagi

1 December 2018 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
PKPriya Kalra
Priya Kalra
SMSubodh Kumar Mishra
Subodh Kumar Mishra
SKSurinder Kaur
Surinder Kaur
AKAmit Kumar
Amit Kumar
HPHanumanthappa Krishna Prasad
Hanumanthappa Krishna Prasad
JTJaya Sivaswami Tyagi
Jaya Sivaswami Tyagi
The entry and survival of Mycobacterium tuberculosis (Mtb) within host cells is orchestrated partly by an essential histone-like protein HupB (Rv2986c). Despite being an essential drug target, the lack of structural information has impeded the development of inhibitors targeting the indispensable and multifunctional C-terminal domain (CTD) of HupB. To bypass the requirement for structural information in the classical drug discovery route, we generated a panel of DNA aptamers against HupB protein through systemic evolution of ligands by exponential (SELEX) enrichment. Two G-quadruplex-forming high-affinity aptamers (HupB-4T and HupB-13T) were identified, each of which bound two distinct sites on full-length HupB, with an estimated KD of ∼1.72 μM and ∼0.17 μM, respectively, for the high-affinity sites. While HupB-4T robustly inhibited DNA-binding activity of HupB in vitro, both the aptamers recognized surface-located HupB and significantly blocked Mtb entry into THP-1 monocytic cells (p < 0.0001). In summary, DNA aptamers generated in this study block DNA-binding activity of HupB, inhibit virulent Mtb infection in host cells, and demonstrate aptamers to be inhibitors of HupB functions. This study also illustrates the utility of SELEX in developing inhibitors against essential targets for whom structural information is not available.

1 January 2019 in Analytical Biochemistry
Verified
Journal Article
Closed access
PKPooja Kumari
Pooja Kumari
SLSurabhi Lavania
Surabhi Lavania
STShaifali Tyagi
Shaifali Tyagi
ADAbhijeet Dhiman
Abhijeet Dhiman
DRDeepak Rath
Deepak Rath
JTJaya Sivaswami Tyagi
Jaya Sivaswami Tyagi

8 July 2016 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
KKKohinoor Kaur
Kohinoor Kaur
PKPriyanka Kumari
Priyanka Kumari
SSSaurabh Sharma
Saurabh Sharma
SSSnigdha Sehgal
Snigdha Sehgal
JTJaya Sivaswami Tyagi
Jaya Sivaswami Tyagi
Two-component systems, comprising histidine kinases and response regulators, empower bacteria to sense and adapt to diverse environmental stresses. Some histidine kinases are bifunctional; their phosphorylation (kinase) and dephosphorylation (phosphatase) activities towards their cognate response regulators permit the rapid reversal of genetic responses to an environmental stimulus. DevR-DevS/DosR-DosS is one of the best-characterized two-component systems of Mycobacterium tuberculosis. The kinase function of DevS is activated by gaseous stress signals, including hypoxia, resulting in the induction of ~48-genes DevR dormancy regulon. Regulon expression is tightly controlled and lack of expression in aerobic Mtb cultures is ascribed to the absence of phosphorylated DevR. Here we show that DevS is a bifunctional sensor and possesses a robust phosphatase activity towards DevR. We used site-specific mutagenesis to generate substitutions in conserved residues in the Dimerization and Histidine phosphotransfer domain of DevS and determined their role in kinase/phosphatase functions. In vitro and in vivo experiments, including a novel in vivo phosphatase assay, collectively establish that these conserved residues are critical for regulating kinase/phosphatase functions. Our findings establish DevS phosphatase function as an effective control mechanism to block aerobic expression of the DevR dormancy regulon. Asp-396 is essential for both kinase and phosphatase functions, whereas Gln-400 is critical for phosphatase function. The positive and negative functions perform opposing roles in DevS: the kinase function triggers regulon induction under hypoxia, whereas its phosphatase function prevents expression under aerobic conditions. A finely-tuned balance in these opposing activities calibrates the dormancy regulon response output.